Although the majority of insulin users had prescriptions of insulin over several years prior to breast cancer diagnosis (mean: 8.4 years), we cannot guarantee the sequence of events (insulin exposure and subsequent tumor promotion) because of the potential lag time in the detection of the tumor. The gene discussed is INS; the disease is breast carcinoma.